Journal of Nanobiotechnology,
Год журнала:
2023,
Номер
21(1)
Опубликована: Сен. 23, 2023
Abstract
Patients
with
inflammatory
bowel
disease
(IBD)
always
suffer
from
severe
abdominal
pain
and
appear
to
be
at
high
risk
for
colorectal
cancer.
Recently,
the
co-delivery
of
targeted
drugs
gut
microbiota
has
developed
into
an
attractive
strategy.
A
new
strategy
using
fermentation
overcome
interspace
diffuse
resistance
mucus
layer
control
drug
release
in
sites
(IBS
sites)
not
yet
been
available.
Here,
we
designed
alginate
hydrogel
microsphere
encapsulating
bifidobacterium
(Bac)
drug-modified
nanoscale
dietary
fibers
(NDFs).
The
is
responsible
protecting
acidic
multi-enzymatic
environments
delivering
colorectum.
Subsequently,
Bac
by
digesting
NDFs
proteins
as
carbon
nitrogen
sources
can
promote
play
a
probiotic
role
microbiota.
In
vitro
evidence
indicated
that
small-sized
NDF
(NDF-1)
could
significantly
short-chain
fatty
acid
(SCFA)
expression.
Notably,
NDF-1
microspheres
showed
boost
5-ASA
IBS
sites,
resulting
amelioration
inflammation
remodeling
chronic
colitis
mice.
This
study
controlled
system
based
on
microbial
treatment
IBD.
Advanced Materials,
Год журнала:
2023,
Номер
36(6)
Опубликована: Сен. 19, 2023
Abstract
Compared
to
injection
administration,
oral
administration
is
free
of
discomfort,
wound
infection,
and
complications
has
a
higher
compliance
rate
for
patients
with
diverse
diseases.
However,
reduces
the
bioavailability
medicines,
especially
biologics
(e.g.,
peptides,
proteins,
antibodies),
due
harsh
gastrointestinal
biological
barriers.
In
this
context,
development
prosperity
nanotechnology
have
helped
improve
bioactivity
availability
medicines.
On
basis,
first,
barriers
are
discussed,
then
nanomedicine
based
on
organic
inorganic
nanomaterials
their
biomedical
applications
in
diseases
reviewed.
Finally,
challenges
potential
opportunities
future
nanomedicine,
which
may
provide
vital
reference
eventual
clinical
transformation
standardized
production
put
forward.
Advanced Materials,
Год журнала:
2023,
Номер
36(14)
Опубликована: Дек. 13, 2023
The
treatment
outcomes
of
oral
medications
against
ulcerative
colitis
(UC)
have
long
been
restricted
by
low
drug
accumulation
in
the
mucosa
and
subsequent
unsatisfactory
therapeutic
efficacy.
Here,
high-performance
pluronic
F127
(P127)-modified
gold
shell
(AuS)-polymeric
core
nanotherapeutics
loading
with
curcumin
(CUR)
is
constructed.
Under
near-infrared
irradiation,
resultant
P127-AuS@CURs
generate
transient
mild
photothermia
(TMP;
≈42
°C,
10
min),
which
facilitates
their
penetration
through
colonic
mucus
favors
multiple
cellular
processes,
including
cell
internalization,
lysosomal
escape,
controlled
CUR
release.
This
strategy
relieves
intracellular
oxidative
stress,
improves
wound
healing,
reduces
immune
responses
polarizing
proinflammatory
M1-type
macrophages
to
anti-inflammatory
M2-type.
Upon
administration
hydrogel-encapsulating
plus
intestinal
intralumen
TMP,
effects
acute
chronic
UC
are
demonstrated
be
superior
those
a
widely
used
clinical
drug,
dexamethasone.
(+
TMP)
elevates
proportions
beneficial
bacteria
(e.g.,
Lactobacillus
Lachnospiraceae),
whose
metabolites
can
also
mitigate
symptoms
regulating
genes
associated
antioxidation,
anti-inflammation,
healing.
Overall,
TMP
offers
promising
approach
enhance
noninvasive
medicines
UC.
Nano Letters,
Год журнала:
2023,
Номер
23(18), С. 8593 - 8601
Опубликована: Авг. 25, 2023
Despite
the
great
progress
of
current
bacterially
based
biotherapeutics,
their
unsatisfying
efficacy
and
underlying
safety
problems
have
limited
clinical
application.
Herein,
inspired
by
probiotic
Escherichia
coli
strain
Nissle
1917,
probiotic-derived
outer
membrane
vesicles
(OMVs)
are
found
to
serve
as
an
effective
therapeutic
platform
for
treatment
inflammatory
bowel
disease
(IBD).
To
further
enhance
effect,
OMV-encapsulating
manganese
dioxide
nanozymes
constructed,
named
nanoprobiotics,
which
can
adhere
inflamed
colonic
epithelium
eliminate
intestinal
excess
reactive
oxygen
species
in
murine
IBD
model.
Moreover,
combined
with
anti-inflammatory
medicine
metformin,
nanoprobiotics
could
remold
pro-inflammatory
microenvironment,
improve
overall
richness
diversity
gut
microbiota,
exhibit
better
than
commercial
chemotherapeutics.
Importantly,
insignificant
overt
systemic
toxicity
this
was
observed.
By
integrating
cytokine
storm
calm
biotherapy,
we
develop
a
safe
bionanoplatform
inflammation-mediated
diseases.
ACS Nano,
Год журнала:
2024,
Номер
18(9), С. 7123 - 7135
Опубликована: Фев. 23, 2024
Inflammatory
bowel
disease
(IBD)
is
strongly
related
to
the
occurrence
of
accumulation
toxic
reactive
oxygen
species
(ROS),
inflammation
mucosa,
and
an
imbalance
intestinal
microbes.
However,
current
treatments
largely
focus
on
a
single
factor,
yielding
unsatisfactory
clinical
outcomes.
Herein,
we
report
biocompatible
IBD-targeted
metabolic
nanoregulator
(TMNR)
that
synergistically
regulates
cellular
bacterial
metabolism.
The
TMNR
comprises
melanin-gallium
complex
(MNR)
encapsulated
within
thermosensitive
colitis-targeting
hydrogel,
all
composed
natural
FDA-approved
components.
confers
superior
broad-spectrum
antioxidant
properties,
effectively
scavenging
(ROS)
blocking
inflammatory
signaling
pathways.
presence
Ga3+
in
selectively
disrupts
iron
metabolism
pathogenic
microorganisms
due
its
structural
resemblance
atom.
Additionally,
incorporating
injectable
hydrogel
enables
targeted
delivery
regions,
prolonging
their
retention
time
providing
physical
barrier
function
for
optimizing
IBD
treatment
efficacy.
Collectively,
modulates
redox
balance
inflamed
colonic
epithelial
tissue
microorganisms,
thereby
eliminating
restoring
homeostasis
against
IBD.
Hence,
this
work
presents
comprehensive
approach
precise
spatiotemporal
regulation
microenvironmental
treatment.
Pharmaceutics,
Год журнала:
2024,
Номер
16(3), С. 431 - 431
Опубликована: Март 21, 2024
The
intestine
is
essential
for
the
modulation
of
nutrient
absorption
and
removal
waste.
Gut
pathologies,
such
as
cancer,
inflammatory
bowel
diseases
(IBD),
irritable
syndrome
(IBS),
celiac
disease,
which
extensively
impact
gut
functions,
are
thus
critical
human
health.
Targeted
drug
delivery
to
tackle
these
diseases,
improve
therapy
efficacy,
minimize
side
effects.
Recent
strategies
have
taken
advantage
both
active
passive
nanocarriers,
designed
protect
until
it
reaches
correct
site
modulate
release
via
use
different
physical–chemical
strategies.
In
this
systematic
review,
we
present
a
literature
overview
nanocarriers
used
in
set
chronic
intestinal
highlighting
rationale
behind
controlled
therapies.
overall
aim
provide
reader
with
useful
information
on
current
approaches
targeting
novel
therapeutic
The Journal of Immunology,
Год журнала:
2024,
Номер
212(2), С. 208 - 215
Опубликована: Янв. 2, 2024
Abstract
The
gut
microbiota,
predominantly
residing
in
the
colon,
is
a
complex
ecosystem
with
pivotal
role
host
immune
system.
Dysbiosis
of
microbiota
has
been
associated
various
diseases,
and
there
an
urgent
need
to
develop
new
therapeutics
that
target
microbiome
restore
functions.
This
Brief
Review
discusses
emerging
therapeutic
strategies
focus
on
oral
delivery
systems
for
modulating
microbiome.
These
include
genetic
engineering
probiotics,
probiotic-biomaterial
hybrids,
dietary
fibers,
microbial
metabolites,
antimicrobial
peptides,
RNA,
antibiotics.
Engineered
formulations
have
demonstrated
promising
outcomes
reshaping
influencing
responses
preclinical
studies.
By
leveraging
these
approaches,
interplay
between
system
can
be
harnessed
development
novel
against
cancer,
autoimmune
disorders,
allergies.
